Ownership and insider activity for Relay Therapeutics, Inc. (RLAY): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
Price
| Price | $18.84 |
| Market Cap | $4.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-08 | Bergstrom Donald A | S-Sale | 8,530 | $162K |
| 2026-09-08 | Catinazzo Thomas | S-Sale | 17,717 | $336K |
| 2026-09-08 | Patel Sanjiv | S-Sale | 48,199 | $913K |
| 2026-08-26 | Rahmer Peter | S-Sale | 4,508 | $90K |
| 2026-08-25 | SVF Pauling (Cayman) Ltd | S-Sale | 6,000,000 | $116.4M |
| 2026-08-17 | Patel Sanjiv | S-Sale | 48,199 | $980K |
| 2026-08-14 | Catinazzo Thomas | S-Sale | 17,717 | $350K |
| 2026-07-28 | Catinazzo Thomas | S-Sale | 1,459 | $27K |
| 2026-07-28 | Rahmer Peter | S-Sale | 748 | $14K |
| 2026-07-28 | Bergstrom Donald A | S-Sale | 2,237 | $42K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $421.5M | $42.0M | $447.6M | $280.1M | $151.8M | $143.7M | $124.3M | $84.0M |
| Short-term Investments | 0 | $313.9M | $230.4M | $678.0M | $847.1M | $606.4M | $657.0M | $470.5M |
| Receivables | 0 | 0 | $82.7M | $4.9M | $5.2M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | $12.1M | 0 | 0 | 0 |
| Total Current Assets | $424.1M | $360.5M | $770.1M | $976.2M | $1.02B | $770.1M | $809.2M | $578.3M |
| Property, Plant & Equipment | $3.6M | $31.7M | $28.8M | $27.3M | $75.4M | $68.9M | $57.7M | $41.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $2.3M | $2.3M | $2.3M | $2.3M | 0 |
| Total Assets | $428.6M | $393.1M | $799.8M | $1.01B | $1.10B | $844.0M | $871.3M | $621.3M |
| Accounts Payable | $4.7M | $7.0M | $6.4M | $8.3M | $10.6M | $9.2M | $14.1M | $7.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.9M | $12.0M | $13.6M | $24.3M | $63.7M | $30.3M | $50.7M | $25.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $539.5M | $573.5M | $36.5M | $110.6M | $149.6M | $92.0M | $93.5M | $54.3M |
| Retained Earnings | -$114.2M | -$189.5M | -$404.2M | -$768.1M | -$1.06B | -$1.40B | -$1.74B | -$2.01B |
| Total Equity | -$110.9M | -$180.4M | $763.3M | $897.8M | $950.2M | $752.0M | $777.8M | $567.1M |
| Total Debt | $178000 | $24.8M | $24.4M | $22.9M | $57.7M | $53.5M | $48.5M | $32.5M |
| Net Debt | -$421.3M | -$331.0M | -$653.6M | -$935.2M | -$941.2M | -$696.6M | -$732.8M | -$522.1M |
| Working Capital | $417.2M | $348.6M | $756.5M | $951.9M | $955.8M | $739.8M | $758.5M | $552.7M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 18.27 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 10.99 |
Profitability
| Return on Equity | -48.76% |
| Return on Invested Capital | -50.50% |
| Return on Assets | -44.50% |
| Gross Margin | -566.59% |
| Operating Margin | -2999.38% |
| Net Margin | -2763.64% |
Related companies: AMLX · CVAC · IMTX · INBX · NKTR · ORIC · SANA
Explore sector: Healthcare · Biotechnology
More sections of RLAY: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks